ReviewJournal of ovarian research2026
Decoding the endothelin-1 network: molecular drivers of ovarian cancer malignancy and new therapeutic horizons.
Review in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
This review provides an in-depth analysis of the key regulatory pathways involving endothelin-1 (ET-1) and its receptors in the progression of ovarian cancer. As one of the most common malignancies affecting the female reproductive system, ovarian cancer exhibits complex pathogenesis and limited treatment options, making it a critical focus in oncology research. ET-1, a potent vasoconstrictive peptide with diverse biological functions, is implicated not only in normal physiological processes but also plays a pivotal role in ovarian cancer initiation, progression, invasion, metastasis, and chemoresistance. The article begins by outlining the fundamental features of ovarian cancer, including its major histopathological subtypes, incidence, and mortality rates. It then examines the structural and functional aspects of ET-1 and its receptors, elucidating their multifaceted roles in ovarian cancer pathobiology, such as promoting tumor cell proliferation, inhibiting apoptosis, inducing angiogenesis, facilitating epithelial-mesenchymal transition (EMT), mediating chemotherapy resistance, and enhancing cell adhesion and invasion. Furthermore, the review highlights the therapeutic potential of targeting ET-1 signaling pathways, encompassing strategies such as inhibition of ET synthesis, receptor antagonism, and combination therapies. Finally, it discusses future research directions aimed at advancing precision medicine approaches for ovarian cancer treatment.
Indexed as
Identifiers
42919395What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.